Metraipolis › archive › dc_f1926f7ecff2
Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens — Europe PMC PMID:40106399
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40106399
- DOI
- 10.1371/journal.pone.0318940
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T12:00:32.830Z
- SHA-256 of the archived text
82a8c7e9b3d9198c9ec50901e0f6286509e820b761257dfa19f86302598e468b- Stable URL of this page
https://metraipolis.com/documento/dc_f1926f7ecff2
How to cite
Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens — Europe PMC PMID:40106399 — Europe PMC (en), https://europepmc.org/article/MED/40106399 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f1926f7ecff2 (Metraipolis archive dc_f1926f7ecff2, sha256 82a8c7e9b3d9198c9ec50901e0f6286509e820b761257dfa19f86302598e468b)
BibTeX
@misc{dcf1926f7ecff2,
title = {Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens — Europe PMC PMID:40106399},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40106399},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f1926f7ecff2; sha256 82a8c7e9b3d9198c9ec50901e0f6286509e820b761257dfa19f86302598e468b},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40106399. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Approximately 130 000 infants acquire HIV annually despite global maternal antiretroviral therapy scale-up. We evaluated the potential clinical impact and cost-effectiveness of offering long-acting, anti-HIV broadly neutralizing antibody (bNAb) prophylaxis to infants in three distinct settings. Methods: We simulated infants in Côte d'Ivoire, South Africa, and Zimbabwe using the Cost-Effectiveness of Preventing AIDS Complications-Pediatric (CEPAC-P) model. We modeled strategies offering a three-bNAb combination in addition to WHO-recommended standard-of-care oral prophylaxis to infants: a) with known, WHO-defined high-risk HIV exposure at birth (HR-HIVE); b) with known HIV exposure at birth (HIVE); or c) with or without known HIV exposure (ALL). Modeled infants received 1-dose, 2-doses, or Extended (every 3 months through 18 months) bNAb dosing. Base case model inputs included 70% bNAb efficacy (sensitivity analysis range: 10-100%), 3-month efficacy duration/dosing interval (1-6 months), and $20/dose cost ($5-$100/dose). Outcomes included pediatric HIV infections, life expectancy, lifetime HIV-related costs, and incremental cost-effectiveness ratios (ICERs, in US$/year-of-life-saved [YLS], assuming a ≤ 50% GDP per capita cost-effectiveness threshold). Findings: The base case model projects that bNAb strategies targeting HIVE and ALL infants would prevent 7-26% and 10-42% additional pediatric HIV infections, respectively, compared to standard-of-care alone, ranging by dosing approach. HIVE-Extended would be cost-effective (cost-saving compared to standard-of-care) in Côte d'Ivoire and Zimbabwe; ALL-Extended would be cost-effective in South Africa (ICER: $882/YLS). BNAb strategies targeting HR-HIVE infants would result in greater lifetime costs and smaller life expectancy gains than HIVE-Extended. Throughout most bNAb efficacies and costs evaluated in sensitivity analyses, targeting HIVE infants would be cost-effective in Côte d'Ivoire and Zimbabwe, and targeting ALL infants would be cost-effective in South Africa. Interpretation: Adding long-acting bNAbs to current standard-of-care prophylaxis would be cost-effective, assuming plausible efficacies and costs. The cost-effective target population would vary by setting, largely driven by maternal antenatal HIV prevalence and postpartum incidence. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-03-19). Identificativi: PMID 40106399 · PMCID PMC11922280 · DOI 10.1371/journal.pone.0318940. Descrittori MeSH principali: HIV Infections; HIV Antibodies; Anti-HIV Agents; Infectious Disease Transmission, Vertical; Broadly Neutralizing Antibodies. Pagina: https://europepmc.org/article/MED/40106399 — https://doi.org/10.1371/journal.pone.0318940. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T10:21:18.020Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.